Sema4D silencing increases the sensitivity of nivolumab to B16-F10 resistant melanoma via inhibiting the PI3K/AKT signaling pathway

Melanoma is a common skin tumor that causes a high rate of mortality, especially in Europe, North America and Oceania. Immunosuppressants such as anti-PD-1 have been used in the treatment of malignant melanoma, however, nearly 60% of patients do not respond to these treatments. Sema4D, also called C...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Zhuo, Zhang, Duoli, Wang, Fang, Liu, Jiao, Sun, Yuhong, Anuchapreeda, Songyot, Tima, Singkome, Xiao, Zhangang, Duangmano, Suwit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PeerJ Inc. 2023
Materias:
Biochemistry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10122458/
https://www.ncbi.nlm.nih.gov/pubmed/37096066
http://dx.doi.org/10.7717/peerj.15172

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10122458/
https://www.ncbi.nlm.nih.gov/pubmed/37096066
http://dx.doi.org/10.7717/peerj.15172

Ejemplares similares